Cannabis Produced Clinical Response in 10 of 11 Crohn's Disease Patients Who Had Failed All Other Treatments

The Study

Naftali and colleagues at the Department of Gastroenterology and Hepatology at Meir Medical Center, affiliated with Tel Aviv University's Sackler Faculty of Medicine, enrolled 21 patients with active Crohn's disease who had failed everything.

The design was elegant in concept: cannabis cigarettes containing 115 mg of THC versus placebo cigarettes made from the same plant material with THC chemically extracted. The flower looked the same, smelled similar, and was rolled identically. Patients smoked twice daily for 8 weeks, with a 2-week follow-up washout period.

The primary endpoint was remission — defined as a Crohn's Disease Activity Index (CDAI) score below 150. The secondary endpoint was clinical response — a drop in CDAI of at least 100 points. This distinction would prove critical to understanding what the study actually found versus what the world would claim it found.

The Results

Read that again carefully, because it contains the single most misunderstood result in the history of cannabis research.

The cannabis group improved dramatically. CDAI scores dropped from 330 to 152 in the treatment group versus 373 to 306 in placebo. Three patients were weaned off corticosteroids entirely. Appetite improved. Sleep improved. Pain decreased. For patients who had exhausted every approved treatment option, this was life-changing relief.

But the primary endpoint failed. The study was designed to test whether cannabis could induce remission. It could not — at least not at a rate statistically distinguishable from placebo in this small sample.

What the Internet Got Wrong

Within months of publication, the study went viral — and the nuance was the first casualty.

Myth vs. Reality

✕Myth

A new study proves marijuana causes complete remission of Crohn's disease

✓Reality

The study explicitly states that its primary endpoint — remission — was NOT achieved. Cannabis produced significant clinical improvement (response) but could not induce complete remission at a statistically significant rate.

The Evidence

Snopes rated this claim FALSE. The study's own conclusion begins: 'Although the primary end point of the study (induction of remission) was not achieved...'

Headlines stripped away the critical distinction between response and remission. "Cannabis cures Crohn's" ricocheted across social media. Snopes eventually published a fact-check rating the claim FALSE, documenting years of viral misrepresentation of a single 21-person pilot study. Celebrity endorsements amplified the distortion further.

The irony is that the actual findings were remarkable enough without exaggeration. A 90% clinical response rate in patients who had failed every available treatment is extraordinary. Three patients off steroids is clinically meaningful. But "helps symptoms significantly" doesn't go viral. "Cures Crohn's" does.

This pattern — legitimate promising research distorted into miracle claims — is one of the most persistent problems in cannabis science communication. It undermines the credibility of real research and creates unrealistic expectations for patients who desperately need accurate information.

Why Cannabis Affects the Gut

The gastrointestinal tract is one of the most cannabinoid-rich environments in the body. The biological basis for cannabis affecting Crohn's disease is not speculation — it is well-established physiology.

This multi-target mechanism — simultaneously addressing inflammation, barrier function, motility, and pain — explains why cannabis produces such broad symptomatic improvement in IBD patients. It also explains a critical limitation: the symptom relief may outpace and mask the actual anti-inflammatory effect, making patients feel better while disease progression continues silently.

The Naftali Arc: A Decade of Evidence

Naftali's 2013 trial was not an isolated experiment. It was the centerpiece of a systematic research program that has unfolded over more than a decade — and the later studies add crucial context.

The 2021 follow-up is the study that completes the picture. It confirmed the symptomatic benefit first observed in 2013 while revealing its critical limitation: cannabis makes Crohn's patients feel better without healing the underlying inflammation. In modern IBD treatment, where mucosal healing is the gold standard for disease control, this distinction is everything. Feeling better while inflammation silently progresses means continued tissue damage, stricture formation, and eventual surgical intervention.

The Controversy

The editorials that accompanied publication exposed the scientific community's ambivalence.

Schicho and Storr, writing in Pharmacology, praised the trial as confirmation of "what has been suggested for a long time from experimental studies" — that cannabinoids have genuine anti-inflammatory potential in IBD. They emphasized the strong preclinical rationale and called for larger studies.

But Vu, Melmed, and Targan from Cedars-Sinai's IBD Center struck a more cautious note in their editorial "Weeding out the facts: the reality about cannabis and Crohn's disease." They highlighted the blinding problem — almost every patient could tell whether they were receiving cannabis or placebo due to psychoactive effects. Except for two placebo patients, all participants correctly identified their group assignment.

The Cochrane Collaboration's 2018 systematic review was the most damning formal assessment. It assigned the evidence "very low certainty" and concluded that "no firm conclusions regarding the efficacy and safety" of cannabis for Crohn's disease could be drawn from this trial alone. The review cited high risk of bias from blinding failure, small sample size, sparse data, and very serious imprecision.

The Bigger Question: Feeling Better vs. Being Better

This study crystallizes a tension that runs through much of cannabis medicine: the gap between symptomatic relief and disease modification.

For a patient with treatment-resistant Crohn's who cannot eat, cannot sleep, and lives in constant pain, symptom relief is not trivial. It is the difference between functioning and not functioning. Three patients in this trial stopped taking corticosteroids — drugs that cause osteoporosis, diabetes, cataracts, and adrenal suppression with long-term use. That matters.

But Crohn's is a progressive disease. Uncontrolled inflammation causes cumulative, irreversible damage. Strictures narrow the bowel. Fistulas create abnormal connections between organs. Each surgical resection removes intestine that cannot be replaced. If cannabis makes a patient feel well enough to delay or refuse proven anti-inflammatory therapy, the long-term outcome could be worse despite the short-term improvement.

This is precisely what Naftali's 2021 follow-up confirmed: cannabis improved symptoms and quality of life, but endoscopy showed the gut inflammation was unchanged. The patients felt better. The disease was not.

The Researcher

Timna Naftali is a professor of gastroenterology at Tel Aviv University's Sackler Faculty of Medicine and heads the IBD service at Meir Medical Center in Kfar Saba, Israel. She was the first researcher to conduct controlled clinical trials of cannabis for inflammatory bowel disease — a decision that required significant professional courage in a field where cannabis research carried stigma.

She established the Gastro Cannabis Laboratory at Meir Medical Center to investigate the mechanisms by which cannabinoids affect the gastrointestinal tract. Her research program has been notably honest: when her CBD trial failed (2017), she published it. When her larger trial showed symptom benefit without mucosal healing (2021), she reported both findings without spin. Her body of work represents the most rigorous clinical investigation of cannabis for IBD in the world.

What This Means Today

Frequently Asked Questions

Does cannabis treat Crohn's disease?

Cannabis significantly improves symptoms in patients with active Crohn's disease, including pain, appetite, sleep, and overall well-being. However, controlled trials have not shown that it induces reliable remission or heals gut inflammation. It appears to be a potent symptomatic treatment rather than a disease-modifying therapy. Patients should not substitute cannabis for proven anti-inflammatory treatments without medical guidance.

Should Crohn's patients try cannabis?

This is a conversation for your gastroenterologist. Cannabis may be a reasonable adjunct for symptom management, especially in patients who have not responded to conventional therapy. But it should not replace immunomodulators or biologics that target the underlying inflammation. Non-smoked preparations (oils, capsules, vaporization) are strongly preferred — smoking is a known trigger for Crohn's flares.

Why did the media say cannabis 'cures' Crohn's?

The study was widely misinterpreted. The 90% clinical response rate (symptom improvement) was conflated with remission (disease control). Snopes rated the viral claim that cannabis causes "complete remission of Crohn's disease" as FALSE. The study's own conclusion states that its primary endpoint of remission induction was not achieved.

Did the CBD-only trial work?

No. Naftali's 2017 follow-up testing low-dose CBD alone (10 mg twice daily) for Crohn's showed no benefit over placebo. This suggests THC, not CBD, drives the symptomatic improvement — though the CBD dose may have been too low for meaningful effect.